SCHEMBL3246386

SCHEMBL3246386

COC(=O)Cc1ccc(C(C)(C)C)c(N)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.65
▸ GAA P10253 2/20 0.65
▸ GFER P55789 1/20 0.65
▸ ANO1 Q5XXA6 1/20 0.48
▸ CYP4F2 P78329 1/20 0.46
▸ CYP4A11 Q02928 1/20 0.46
▸ SMN1; SMN2 Q16637 4/20 0.46
▸ MAPT P10636 3/20 0.46
▸ LMNA P02545 1/20 0.46
▸ HSP90AB1 P08238 1/20 0.45
▸ SLC7A5 Q01650 1/20 0.43
▸ HPGD P15428 3/20 0.43
▸ TSHR P16473 2/20 0.43
▸ PDK2 Q15119 1/20 0.42
▸ NR1H4 Q96RI1 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ NPC1 O15118 3/20 0.39
▸ RAB9A P51151 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16267890 0.86 ALDH1A1 (0.63) ALDH1A1GAAGFERCYP4F2CYP4A11
SCHEMBL7237331 0.82 ALDH1A1 (0.75) ALDH1A1GAAGFERCYP4F2CYP4A11
SCHEMBL30565426 0.82 ALDH1A1 (0.75) ALDH1A1GAAGFERCYP4F2CYP4A11
SCHEMBL20598923 0.79 ALDH1A1 (0.62) ALDH1A1GAAGFERCYP4F2CYP4A11
SCHEMBL287469 0.79 GAA (1.00) ALDH1A1GAAGFERCYP4F2CYP4A11
SCHEMBL8147823 0.79 ALDH1A1 (0.71) ALDH1A1GAAGFERCYP4F2CYP4A11
SCHEMBL20045098 0.79 ALDH1A1 (0.71) ALDH1A1GAAGFERCYP4F2CYP4A11
SCHEMBL3784804 0.78 ALDH1A1 (0.69) ALDH1A1GAAGFERCYP4F2CYP4A11
SCHEMBL5734658 0.78 ALDH1A1 (0.69) ALDH1A1GAAGFERCYP4F2CYP4A11
Hydrochloric Acid SCHEMBL11216073 0.78 GAA (0.97) ALDH1A1GAAGFERCYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1167366-B1 AMINE DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2010-05-05 — — EP disclosed
CN-1162427-C Amine derivatives compounds ������������ʽ���� 2004-08-18 — — CN disclosed
US-6562849-B1 Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. SANKYO COMPANY, LIMITED (JP) 2003-05-13 — — US disclosed
US-20030078426-A1 Amine derivative compounds SANKYO COMPANY, LIMITED (JP) 2003-04-24 — — US disclosed
CN-1354750-A Amine derivatives compounds SANKYO CO (JP) 2002-06-19 — — CN disclosed
EP-1167366-A1 AMINE DERIVATIVES Sankyo Company, Limited (JP) 2002-01-02 — — EP disclosed
EP-0763524-B1 Urea and amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prophylactic use SANKYO CO (JP) 2000-08-23 — — EP disclosed
US-6040339-A TREATMENT AND PROPHYLAXIS OF HYPERCHOLESTEREMIA OR ARTERIOSCLEROSIS IN A MAMMAL SANKYO COMPANY, LIMITED (JP) 2000-03-21 — — US disclosed
US-5880147-A Amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prohylactic use SANKYO COMPANY, LIMITED (JP) 1999-03-09 — — US disclosed
EP-0763524-A1 Urea and amide derivatives having ACAT inhibitory activity, their preparation and their therapeutic and prophylactic use SANKYO COMPANY LIMITED (JP) 1997-03-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078426-A1 Amine derivative compounds H1-10, APOB, PRMT1 ALDH1A1 874/4885GAA 3055/4885GFER 1091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback